REPLY
6.7.2021 09:32:07 CEST | Business Wire | Press release
Reply announced today that it has developed an end-to-end solution architecture for autonomous mobile robots (AMR) on Microsoft Azure that enables new business applications across industries, reduces upfront costs and allows for the rapid implementation of customer-specific robotics use cases.
The solution combines Microsoft Azure services, the agility of Boston Dynamics' SPOT and Reply’s knowledge of intelligent cloud computing services, edge computing and artificial intelligence. To demonstrate the capabilities of a scalable and versatile robotics platform, Reply implemented an automated vehicle-damage-detection solution for rental or leasing companies that leverages this architecture. In fact, rental or leasing companies must inspect vehicles for any damage after they are returned in order to ensure the safety and quality of their fleet for their customers. This is usually done in the time- and cost-consuming manual process of walking around the car, visually inspecting it, assessing the severity of the damage and conducting a damage report.
Reply integrates Azure Cognitive Services, Machine Learning and DevOps as well as Power Apps and Power BI. Thanks to Azure's intelligent service foundation, agile workflows and machine learning, this process can be fully automated. Using computer vision, SPOT moves freely through the parking area and scans the license plates to find the right vehicle. Once detected, it walks around the vehicle to record its condition by continuously collecting visual data with its camera and sensors. This information is processed “on the edge” or transmitted to the cloud, where advanced image recognition and machine leaning algorithms perform the damage detection. All detected damages are saved in the return protocol, and they can be presented to the customer and the fleet manager for approval.
“This platform sets the power of Microsoft Azure on the move by bringing it from the Cloud to the Edge and into highly advanced mobile robotic devices, giving them the autonomy to unlock novel business use cases. Thanks to the agile reference architecture, we are able to implement customer-specific use cases in various industries that include all types of mobile robots or drones ”, comments Filippo Rizzante, CTO Reply.
“Reply is a long-term, trusted partner in delivering Azure IoT solutions, and we’re delighted to continue our collaboration on this new scalable robotics offering. By leveraging Microsoft Azure, we can help accelerate this transformation by making it easier for businesses to bring AI and analytics capabilities to these autonomous systems in a consistent and secure way,” adds Lakecia Gunter, Vice President and GM, Global IOT Channel at Microsoft.
With their agility, autonomous mobile robots (AMR) are able to move independently from a central infrastructure on terrain that is not traditionally designed for robots. They can be used in hazardous environments and environments, that are harmful to people. According to ResearchAndMarkets.com, the global market for automated guided vehicle (AGV) and AMR is expected to reach $13.2 Billion by 2026 with a growth rate of around 35%. Both AGVs and AMRs collectively are going to cross the installed base of 1.5 Million in the next 5 years to make mobile robots a new normal in our day-to-day operational activities.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Source Global Mobile Robots (AGV & AMR) Market:
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005133/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom